Your browser does not support JavaScript!

Matières premières

351 entreprises et organismes intervenants dans le domaine 'Matières premières', classés par activité.

Rejoignez la communauté
ABBOTT
est cité dans une actualité de FierceBiotech
Il y a 6 jours

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

Il y a 1 semaine
In its first evaluation of real-world data derived from its FreeStyle Libre continuous glucose monitor in people with Type 2 diabetes, Abbott found that the system was able to significantly reduce...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

Il y a 3 semaines
Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2?...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 17/05/2019

EuroBiotech Report—Bayer's $150M site, Merck, F-star, Philogen round and roxa data

Le 16/05/2019
In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 15/05/2019

Merck KGaA retools F-star pact, walks away from lead PD-L1 drug

Le 14/05/2019
Merck KGaA has revised the bispecific immuno-oncology antibody agreement it struck with F-star in 2017. The Big Pharma has exercised its option on a discovery program but walked away from phase 1...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 07/05/2019

Abbott smartens up its smartphone-based ICM with more accurate detection

Le 06/05/2019
Abbott has launched a new, smarter version of its small implantable monitor for detecting irregular heartbeats that the company says now reduces the rate of false detection by 97%....
www.fiercebiotech.com
Nouvelle réponse - Le 06/05/2019
Combien de temps dure le médicament plasmocure dans le corps d'un patient?
INVIVOGEN
à répondu :

Bonjour.

Ceci est un réactif pour recherche uniquement.

Il ne peut en aucun cas être utiliser chez l'homme ni pour un usage vétérinaire.

Cordialement.

Dominique Chevrier

MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 15/04/2019

EuroBiotech Report—Bayer boosts U.S. research workforce, Poxel sees diabetes success and Kymab turns to Merck KGaA for next CEO

Le 12/04/2019
In this week's EuroBiotech Report, Bayer is planting seeds in Kendall Square, Poxel saw its shares jump, Kymab turns to former German Merck executive, J&J Vision and Edwards spend millions on...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 10/04/2019

Roivant-backed Merck Serono spinout hits phase 3 diabetes goal; NDA on the horizon

Le 09/04/2019
Poxel, a biotech spun out of Germany’s Merck and based in France, and Japanese partner Sumitomo Dainippon Pharma have announced positive data from their late-stage diabetes study in Japan. The pair...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 09/04/2019

U.K. biotech Kymab nabs new CEO from Merck KGaA

Le 08/04/2019
Kymab has hired on a new CEO, Simon Sturge, to usher the antibody specialist into its next phase of growth. Sturge joins from Merck KGaA, where he oversaw the launches of cancer drug Bavencio and...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 04/04/2019

Dyne starts life with $50M, big biopharma names for muscle disease work

Le 03/04/2019
A new Atlas Venture-incubated startup looking to treat patients with rare forms of muscle diseases has got off a $50 million series A with executives out of Amgen, Editas, Merck and Sarepta at the...
www.fiercebiotech.com
Charger plus d'actualités